Mirae Asset Global Investments Co., Ltd. Altimmune, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$8.22 - $13.81 $219,194 - $368,257	26,666 New	26,666 $271,000
Q3 2023 Oct 26, 2023	BUY	$2.4 - $3.45 $297 - $427	124 Added 0.44%	28,352 $73,000
Q2 2023 Aug 10, 2023	BUY	$3.45 - $5.97 $25,657 - $44,398	7,437 Added 35.77%	28,228 $99,000
Q1 2023 May 04, 2023	BUY	$4.19 - $16.83 $87,114 - $349,912	20,791 New	20,791 $87,000

191

42.4M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $371M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.